Cellares
Address: 341 Allerton Ave,, South San Francisco, San Francisco, CA 94080About Us
Cellares is revolutionizing cell therapy manufacturing. We are developing a one-of-a-kind solution, The Cell Shuttle, to overcome the challenges associated with manufacturing so these life-saving therapies are affordable and widely available to patients who can benefit. The clinical impact of cell therapy in treating cancer has been proven, but this therapeutic approach has several limitations, especially in manufacturing, leaving extremely sick patients waiting for treatment and desperate for hope. Since cell therapy is currently produced for a single patient at a time, it is expensive to manufacture, requiring significant time and resources, and is difficult to scale. Preclinical and clinical scientists, as well as commercial cell therapy manufacturers also lack the options to fully automate their manufacturing process quickly, safely, cost-effectively and at the scale they need. The Cell Shuttle is an automated and closed end-to-end manufacturing solution that is flexible and scalable, enabling customers to run exact processes specified for their cell therapy. Compared with the current manual manufacturing processes for cell therapy, the Cell Shuttle’s next-generation automated manufacturing solution has 10 times the scalability (meaning 10 times more patient doses can be produced simultaneously), enables a three-fold reduction in process failure rates and will reduce the per-patient manufacturing cost by up to 70 percent for most processes.
Sectors
- Equipment & Machinery
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Manufacture
- Contract Research & Development
- Contract Manufacturing
Categories
- Biotechnology
- Biologics
- Processing Equipment
- Cell Therapy
- Cell Therapy Products
- Automation Technology
- Containment Facilities
- Continuous Manufacturing
- Bioprocess Development
- Process Development
- CAR-T Therapies
A PHP Error was encountered
Severity: Notice
Message: Undefined property: stdClass::$company_licence_detail_in
Filename: profile/print_profile.php
Line Number: 302
Backtrace:
File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 302
Function: _error_handler
File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view
File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once
A PHP Error was encountered
Severity: Notice
Message: Undefined property: stdClass::$company_licence_detail_out
Filename: profile/print_profile.php
Line Number: 303
Backtrace:
File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 303
Function: _error_handler
File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view
File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once
A PHP Error was encountered
Severity: Notice
Message: Undefined property: stdClass::$company_licence_detail_distributor
Filename: profile/print_profile.php
Line Number: 304
Backtrace:
File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 304
Function: _error_handler
File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view
File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once
A PHP Error was encountered
Severity: Notice
Message: Undefined property: stdClass::$company_licence_detail_researcher
Filename: profile/print_profile.php
Line Number: 305
Backtrace:
File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 305
Function: _error_handler
File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view
File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once
A PHP Error was encountered
Severity: Notice
Message: Undefined property: stdClass::$company_licence_detail_description
Filename: profile/print_profile.php
Line Number: 306
Backtrace:
File: /home/pharmase/actex_application/views/front_end/profile/print_profile.php
Line: 306
Function: _error_handler
File: /home/pharmase/actex_application/controllers/Profile.php
Line: 483
Function: view
File: /home/pharmase/public_html/index.php
Line: 292
Function: require_once
News
Cellares Raises $257 Million to Industrialize Global Cell Therapy Manufacturing with Breakthrough Automation
This investment round will fund the global buildout of automated IDMO Smart Factories across South San Francisco, CA; Bridgewater, NJ; Leiden, the Netherlands; and Kashiwa City, Japan, to enable commercial launch and unconstrained manufacturing of cell therapies for hundreds of thousands of patients annually.
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
SOUTH SAN FRANCISCO, CA, JUNE 27, 2024 -– Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced that Kite, a Gilead Company, will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle. The data generated in this proof-of-concept evaluation will be utilized to assess viability of the Cell Shuttle as a future manufacturing option for Kite.
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement
(PRINCETON, N.J. & SOUTH SAN FRANCISCO, CA, April 22, 2024) -– Bristol Myers Squibb (NYSE: BMY) and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, today announced a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies in a transaction valued up to $380M in upfront and milestone payments. As part of the agreement, Cellares will optimize, automate, and tech-transfer select Bristol Myers Squibb CAR T cell therapies onto its automated and high-throughput manufacturing platform, the Cell Shuttle™. Cellares will dedicate multiple Cell Shuttle and Cell Q™ systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use. The Cell Shuttles and Cell Qs will be deployed in Cellares’ Smart Factories in the U.S., EU, and Japan.
Cellares and Cabaletta Bio Partner
SOUTH SAN FRANCISCO. Calif., Nov. 6, 2023 – Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program. As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of CABA-201, Cabaletta’s clinical-stage fully human CD19-CAR T cell product candidate, using the Cell Shuttle.
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program
SOUTH SAN FRANCISCO, August 28, 2023 – Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy developer Bristol Myers Squibb (NYSE: BMY) has joined its Technology Adoption Partnership (TAP) program. As part of the agreement, the pharma leader will enter into a proof-of-concept transfer process for the manufacture of one of its CAR-T cell therapies, using Cellares’ automated manufacturing platform, the Cell Shuttle.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com